Gastroesophageal Reflux Disease Market - Forecast(2024 - 2030)
Market Overview
The global Gastroesophageal
Reflux Disease market is forecast to reach $7.81 billion by 2024, growing at a
CAGR of 3.75% during the forecast period 2019-2024. This market is growing
owing to the rise in the global alcohol consumption as well as the surge in
geriatric population and the increasing prevalence of gastroesophageal reflux
disease. Esophageal pH monitoring and esophageal impedance test are diagnostic
tests that measures the amount and type of gastroesophageal reflux in the
esophagus. These tests helps in identifying traces of esophageal stricture.
Key Takeaways
- The North America Region is estimated to dominate the market owing to the rise in the prevalence of the disease as well as the geriatric population. Information on other major region’s Gastroesophageal Reflux Disease market size also mentioned in the final report.
- The rise in the overall consumption of alcohol is considered as a major market driver as an increased alcohol consumption is linked with gastroesophageal reflux disease. Other major market drivers that have been considered are also mentioned in the final report.
- Availability of a large number of OTC products are considered to have a negative effect on the overall market growth. This is owing to the fact that having these products will encourage self-treatment. Other major market limiters mentioned in the full, final report.
Drug Type - Segment Analysis
The major segment in drug type
were held by antacids and are estimated to retain their top position over the
forecast period. This is owing to the easy availability of antacid products in
various forms such as in tablets, powders and syrups. The antacid products are
also estimated to be the fastest growing segment as well and is estimated to
hold a CAGR of 4.3%. Proton pump inhibitors such as Omeprazole provides long-lasting
reduction of stomach acid production. It initiates lower esophageal sphincter
to close which prevents stomach acid to travel back into the bowel.
Geography - Segment Analysis
The North America region is
estimated to hold the largest Gastroesophageal Reflux Disease market share of
32%. This is owing to the rise in geriatric population who are prone to this
disease as well as its increasing prevalence. However, the APAC region was
found to have the fastest growth rate owing to the rise in geriatric population
as well as the growing trend of self-treatment because of the availability of
affordable, over the counter antacids.
Drivers – Gastroesophageal Reflux Disease Market
·
Rising Alcohol Consumption
Studies have
shown that the consumption of alcohol will affect the prevalence of
gastroesophageal reflux disease. The increasing consumption of alcohol will
affect the overall prevalence of the disease and could contribute to the
overall market growth.
·
Rising
Geriatric population
The disease is
more prevalent in elderly people and the growth of the elderly population has
the potential to contribute greatly to the overall gastroesophageal reflux
disease market.
Challenges – Gastroesophageal Reflux Disease Market
·
Availability
of a large number of products
There is a large
amount of products in the market that provides symptomatic treatment. This
factor could be considered as a major challenge to the overall market as people
may not know the difference in benefits between the products. There is also a
lot of over the counter products for this disease as well.
Gastroesophageal Reflux Disease Industry Outlook
Product
launches and acquisitions are the key strategies adopted by the players in the Gastroesophageal
Reflux Disease industry. Gastroesophageal Reflux Disease top 10 companies include
Teva Pharmaceutical Industries Ltd., AstraZaneca, Boston Scientific Corporation,
Eisai Co., Ltd., Endogastric Solutions Inc., Endostim BV, Ironwood
Pharmaceuticals Inc., Jeil Pharmaceutical Co., Ltd., Cheplapharm Arzneimittel GmbH and Pfizer Inc., among others.
Acquisitions/Product Launches
- On October 2019, Cheplapharm Arzneimittel GmbH had announced that it acquired the commercial rights of the acid reflux treatment drug from AstraZeneca for $276 million. However, AstraZeneca will make and sell the drug wherever the rights are not included.
- On November2017, EndoGastric Solution had introduced its new product for Transoral Incisionless Fundoplication procedures. This product is designed to reconstruct the gastroesophageal valve and to restore its function as a reflux barrier.
1.1 Definitions and Scope
2. Gastroesophageal Reflux Disease Market - Executive summary
2.1 Market Revenue, Market Size and Key Trends by Company
2.2 Key Trends by type of Application
2.3 Key Trends segmented by Geography
3. Gastroesophageal Reflux Disease Market
3.1 Comparative analysis
3.1.1 Product Benchmarking - Top 10 companies
3.1.2 Top 5 Financials Analysis
3.1.3 Market Value split by Top 10 companies
3.1.4 Patent Analysis - Top 10 companies
3.1.5 Pricing Analysis
4. Gastroesophageal Reflux Disease Market - Startup companies Scenario Premium
4.1 Top 10 startup company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Market Shares
4.1.4 Market Size and Application Analysis
4.1.5 Venture Capital and Funding Scenario
5. Gastroesophageal Reflux Disease Market - Industry Market Entry Scenario Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis - Top 10 companies
6. Gastroesophageal Reflux Disease Market Forces
6.1 Drivers
6.2 Constraints
6.3 Challenges
6.4 Porters five force model
6.4.1 Bargaining power of suppliers
6.4.2 Bargaining powers of customers
6.4.3 Threat of new entrants
6.4.4 Rivalry among existing players
6.4.5 Threat of substitutes
7. Gastroesophageal Reflux Disease Market -Strategic analysis
7.1 Value chain analysis
7.2 Opportunities analysis
7.3 Product life cycle
7.4 Suppliers and distributors Market Share
8. Gastroesophageal Reflux Disease Market - By Product Type (Market Size -$Million / $Billion)
8.1 Market Size and Market Share Analysis
8.2 Application Revenue and Trend Research
8.3 Product Segment Analysis
9. Gastroesophageal Reflux Disease Market - By Drug (Market Size -$Million / $Billion)
9.1 Antacid
10. Gastroesophageal Reflux Disease - By Application Type (Market Size -$Million / $Billion)
10.1 Segment type Size and Market Share Analysis
10.2 Application Revenue and Trends by type of Application
10.3 Application Segment Analysis by Type
11. Gastroesophageal Reflux Disease- By Geography (Market Size -$Million / $Billion)
11.1 Gastroesophageal Reflux Disease Market - North America Segment Research
11.2 North America Market Research (Million / $Billion)
11.2.1 Segment type Size and Market Size Analysis
11.2.2 Revenue and Trends
11.2.3 Application Revenue and Trends by type of Application
11.2.4 Company Revenue and Product Analysis
11.2.5 North America Product type and Application Market Size
11.2.5.1 U.S
11.2.5.2 Canada
11.2.5.3 Mexico
11.2.5.4 Rest of North America
11.3 Gastroesophageal Reflux Disease- South America Segment Research
11.4 South America Market Research (Market Size -$Million / $Billion)
11.4.1 Segment type Size and Market Size Analysis
11.4.2 Revenue and Trends
11.4.3 Application Revenue and Trends by type of Application
11.4.4 Company Revenue and Product Analysis
11.4.5 South America Product type and Application Market Size
11.4.5.1 Brazil
11.4.5.2 Venezuela
11.4.5.3 Argentina
11.4.5.4 Ecuador
11.4.5.5 Peru
11.4.5.6 Colombia
11.4.5.7 Costa Rica
11.4.5.8 Rest of South America
11.5 Gastroesophageal Reflux Disease- Europe Segment Research
11.6 Europe Market Research (Market Size -$Million / $Billion)
11.6.1 Segment type Size and Market Size Analysis
11.6.2 Revenue and Trends
11.6.3 Application Revenue and Trends by type of Application
11.6.4 Company Revenue and Product Analysis
11.6.5 Europe Segment Product type and Application Market Size
11.6.5.1 U.K
11.6.5.2 Germany
11.6.5.3 Italy
11.6.5.4 France
11.6.5.5 Netherlands
11.6.5.6 Belgium
11.6.5.7 Denmark
11.6.5.8 Spain
11.6.5.9 Rest of Europe
11.7 Gastroesophageal Reflux Disease - APAC Segment Research
11.8 APAC Market Research (Market Size -$Million / $Billion)
11.8.1 Segment type Size and Market Size Analysis
11.8.2 Revenue and Trends
11.8.3 Application Revenue and Trends by type of Application
11.8.4 Company Revenue and Product Analysis
11.8.5 APAC Segment - Product type and Application Market Size
11.8.5.1 China
11.8.5.2 Australia
11.8.5.3 Japan
11.8.5.4 South Korea
11.8.5.5 India
11.8.5.6 Taiwan
11.8.5.7 Malaysia
11.8.5.8 Hong kong
11.8.5.9 Rest of APAC
11.9 Gastroesophageal Reflux Disease - Middle East Segment and Africa Segment Research
11.10 Middle East & Africa Market Research (Market Size -$Million / $Billion)
11.10.1 Segment type Size and Market Size Analysis
11.10.2 Revenue and Trend Analysis
11.10.3 Application Revenue and Trends by type of Application
11.10.4 Company Revenue and Product Analysis
11.10.5 Middle East Segment Product type and Application Market Size
11.10.5.1 Israel
11.10.5.2 Saudi Arabia
11.10.5.3 UAE
11.10.6 Africa Segment Analysis
11.10.6.1 South Africa
11.10.6.2 Rest of Middle East & Africa
12. Gastroesophageal Reflux Disease Market - Entropy
12.1 New product launches
12.2 M&A s, collaborations, JVs and partnerships
13. Gastroesophageal Reflux Disease Market - Industry / Segment Competition landscape Premium
13.1 Market Share Analysis
13.1.1 Market Share by Country- Top companies
13.1.2 Market Share by Region- Top 10 companies
13.1.3 Market Share by type of Application - Top 10 companies
13.1.4 Market Share by type of Product / Product category- Top 10 companies
13.1.5 Market Share at global level - Top 10 companies
13.1.6 Best Practises for companies
14. Gastroesophageal Reflux Disease Market - Key Company List by Country Premium
15. Gastroesophageal Reflux Disease Market Company Analysis
15.1 Market Share, Company Revenue, Products, M&A, Developments
15.2 Abbott
15.3 Astrazeneca Plc
15.4 Daewoong Pharmaceutical Co., Ltd
15.5 Eisai Co , Ltd
15.6 Glaxosmithkline Plc
15.7 Ironwood Pharmaceuticals, Inc
15.8 Johnson Johnson Services, Inc
15.9 Novartis Ag
15.10 Pfizer, Inc
15.11 Raqualia Pharma, Inc
15.12 Reckitt Benckiser Group Plc
15.13 Sfj Pharmaceutical Group
15.14 Sr Pharmaceutical Pvt. Ltd
15.15 Takeda Pharmaceutical Co, Ltd
15.16 Company 15
15.17 Company 16 & More
16.1 Abbreviations
16.2 Sources
17. Gastroesophageal Reflux Disease Market - Methodology
17.1 Research Methodology
17.1.1 Company Expert Interviews
17.1.2 Industry Databases
17.1.3 Associations
17.1.4 Company News
17.1.5 Company Annual Reports
17.1.6 Application Trends
17.1.7 New Products and Product database
17.1.8 Company Transcripts
17.1.9 R&D Trends
17.1.10 Key Opinion Leaders Interviews
17.1.11 Supply and Demand Trends